|
- Hemophilia Therapies - Rare Disease Advisor
Koāte ® (antihemophilic factor [human]), also known as Koāte-DVI, is a human plasma-derived FVIII indicated for the treatment and prevention of bleeding episodes in patients with hemophilia A Initially approved in the US in 1974, the processing methods have been updated over the years to make the product safer from viral contamination
- Acquired Hemophilia Treatment Management - Medscape
Recombinant antihemophilic factor, porcine sequence Historically, porcine factor VIII has provided a good effect A porcine sequence recombinant FVIII (rpFVIII; Obizur) was approved by the US Food and Drug Administration (FDA) in 2014 for treatment of bleeding episodes in adults with acquired hemophilia
- AHF (Antihemophilic Factor): Uses Side Effects
AHF (antihemophilic factor) is a medication that prevents or manages bleeding if you have hemophilia A This condition keeps your blood from clotting as it should so you bleed more than expected A healthcare provider will usually give you this injection in a hospital or clinic setting
|
|
|